REGENXBIO Inc. (NasdaqGS: RGNX)
Health Care · Biotechnology · US
$10.72
-0.42% today · +19.5% 1Y
REGENXBIO Inc. (NasdaqGS: RGNX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $707.66M and employs 371 people.
Over the last twelve months the share price has gained 19.5%, trading between 5.46 and 16.19.
Tweenvest scores REGENXBIO Inc. across four factors: quality 32/100, value 60/100, growth 100/100. Its strongest factor is growth.
RGNX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $707.66M
- Revenue (TTM)
- $174.48M
- P/E
- —
- EPS
- -3.77
- Dividend yield
- —
- Beta (5Y)
- 0.94
- 52-week high
- $16.19
- 52-week low
- $5.46
- Avg volume (3M)
- —
- Shares outstanding
- 66.01M
- Employees
- 371
- Next earnings
- —
About REGENXBIO Inc.
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
- ISIN
- US75901B1070
- Founded
- 2008
- Listed since
- Sep 17, 2015
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $441.75 | +0.55% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.61 | +0.34% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €883.80 | -2.02% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $143.00 | -1.43% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.